<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F180C115-635C-42DD-A5A3-EB11559B15E2"><gtr:id>F180C115-635C-42DD-A5A3-EB11559B15E2</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:otherNames>Alexander</gtr:otherNames><gtr:surname>McNeish</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C9E4FB8A-25B4-4D13-88E6-740B91962BDF"><gtr:id>C9E4FB8A-25B4-4D13-88E6-740B91962BDF</gtr:id><gtr:firstName>Frances</gtr:firstName><gtr:surname>Balkwill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BD748225-DD24-44B9-A132-603B4294301F"><gtr:id>BD748225-DD24-44B9-A132-603B4294301F</gtr:id><gtr:firstName>Norbert</gtr:firstName><gtr:otherNames>Eduard</gtr:otherNames><gtr:surname>Avril</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501974"><gtr:id>5B4D2450-4A81-4D9A-9737-18FC481C82C2</gtr:id><gtr:title>Cytokine antagonists in ovarian cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501974</gtr:grantReference><gtr:abstractText>Ovarian cancer is known as the silent killer because it causes few symptoms until it has spread widely in the abdomen. When a woman is diagnosed with ovarian cancer she is treated with surgery and chemotherapy. However after a period of 1-4 years, the cancer usually returns and is very difficult to treat. 
In past few years we have learnt that growth and spread of cancers is helped by some of the chemicals that naturally control acute inflammation in the body. Inflammation is usually a good thing that helps us fight infection but in the case of cancer and chronic inflammation, these chemicals, called cytokines, are produced in the wrong place and at the wrong time. The usually helpful cytokines have become part of the disease process. This research has led to discovery of new drugs that help people with chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. The drugs stop cytokines working and greatly reduce symptoms, giving great benefit to many severely ill patients. 
Because of the parallels between cancer and inflammation, it is possible that the same drugs may help cancer patients. In our previous research we have found that cytokines can drive ovarian cancer growth and spread. One cytokine that is particularly important is called interleukin 6. Interleukin 6 helps keep cancer cells alive and in turn switches on other inflammatory chemicals that make the cancer and the patient worse. In this trial we will take women with relapsed ovarian cancer and give them a drug that will block the action of interleukin 6 in the cancer. We hope that this will halt the growth and spread of their cancer, and also, may improve the general well being of the patient by reducing other interleukin-6 induced chemicals that can contribute to their often distressing symptoms.</gtr:abstractText><gtr:technicalSummary>Inflammatory cytokine antagonists have useful disease modifying activity in several chronic inflammatory conditions. In view of the mounting evidence that inflammatory cytokines contribute to cancer growth and spread, we wish to investigate the clinical efficacy and biological activity of a neutralising antibody to the cytokine interleukin-6, IL-6, in women with advanced epithelial ovarian cancer. The rationale for conducting this study comes from extensive research into the cytokine and chemokine microenvironment of epithelial ovarian cancer by the principal applicant; and from many experimental and human cancer studies that link inflammatory cytokines with cancer growth and spread. IL-6 is a particularly compelling target in advanced ovarian cancer because of its anti-apoptotic properties and its association with disease severity.
The planned study is an open label Phase II clinical study of CNTO328, a chimeric (murine-human) monoclonal antibody that has shown high affinity for IL-6 in pre-clinical and clinical study and is well tolerated in ongoing Phase I evaluations. Sixteen women with advanced ovarian cancer will receive three intravenous infusions of 12mg/kg CNTO328 at two-week intervals, with the option of further infusions if there is evidence of response (CR, PR, SD). The primary endpoint is disease response, which will be assessed by a combined [18F]-FDG PET/CT scan prior to treatment and at the end of treatment. Secondary endpoints will be changes in IL-6 related biomarkers in plasma and evaluation of quality of life. Tertiary endpoints are quantification of changes in IL-6-related genes and proteins in tumour biopsies and ascites cells prior to and at the end of treatment, and sequential measurement of blood and ascites tumour cells using CellSearch technology.
Median survival of women with platinum-resistant ovarian cancer is approximately 12 months; new treatments are desperately needed. The addition of therapeutic antibodies to standard chemotherapy has improved survival in breast and colorectal cancer but there are currently no antibodies approved for treatment of ovarian cancer. If CNTO328 has clinical efficacy in this proposed phase II trial, our next step will be combination with either first or second line chemotherapy to see if we can improve patient survival. In addition, because we already have information on clinical efficacy and biological activity of TNF-? antagonists in patients with ovarian cancer, and these two cytokines stimulate cancer progression via different intracellular pathways, we would be able to investigate antibody combinations in future clinical trials.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>437270</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>MedImmune</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with MedImmune</gtr:description><gtr:id>EE5BFE2B-75D7-4218-8815-72285EDE2E4C</gtr:id><gtr:impact>Two papers published in Cancer Research in 2015</gtr:impact><gtr:outcomeId>56ceeb9c2c66c7.71220153-1</gtr:outcomeId><gtr:partnerContribution>The partners provided us with know-how and research antibodies. For the IL-6 project MedImmune researchers were authors on two papers published in Cancer Research.</gtr:partnerContribution><gtr:piContribution>We have two separate collaborations with MedImmune. One collaboration paid us to study a new immune-related target in ovarian cancer. The other is a collaboration which provides us with free supplies of an anti-IL-6 antibody and advice and access to their research with this antibody.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Centre of the Cell www.centreofthecell.org</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>16B8CE59-7BBD-45DB-ABD0-BBC0B2DAA87F</gtr:id><gtr:impact>Meet the Scientist CPD for teachers and AS level students. Interaction with school children who visit the Centre of the Cell. Development of Apps to be released in 2016 on biomedical research including one directly related to the CRUK Programme Grant.

The Meet The Scientist event I ran had approximately 30 teachers I regularly interact with 9-16 year olds in Pod visits - we only opened in `Sept 2009. For more details see the website - address above. Over 86,000 participants in Centre of the Cell Activities. I am the Director of Centre of the Cell. we are also planning a submission for a Royal Society summer exhibition linked to results form the current grant and my ERC Advanced grant in collaboration with Cancer Research UK. There will be a d</gtr:impact><gtr:outcomeId>36DD49E0065</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.centreofthecell.org</gtr:url><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Society Summer Exhibition 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>913FE652-EB63-42C2-A6BB-C89F771B2C54</gtr:id><gtr:impact>Our work on the tumour microenvironment and on building a human model of the tumour microenvironment has been selected for the Royal Society Summer Science Exhibition this year.</gtr:impact><gtr:outcomeId>56cee924bc5656.26273006</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>https://royalsociety.org/events/summer-science-exhibition</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2431053</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Building a Human Tumour Microenvironment</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>AC95BE28-F109-4F15-870A-59BBF7EB425D</gtr:id><gtr:outcomeId>5462087f3b9067.64510645</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56078</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Support for Pre-Clinical and Clinical Studies in Infliximab and Sorafenib</gtr:description><gtr:fundingOrg>Queen Mary University of London</gtr:fundingOrg><gtr:id>C3AA5FE5-32A4-4B7A-A0F7-28A9A59A523D</gtr:id><gtr:outcomeId>6696C58C7830</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding (Targeting Cancer-Related Inflammation)</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>F41D785B-F9EB-4D45-802E-5521F0C27CEC</gtr:id><gtr:outcomeId>6CD7CB459A60</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9438</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MedImmune Funding (Validation of CXCR4 as a Therapeutic Target in Ovarian Cancer using an Anti-CXCR4 Antibody, Stage I)</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>2DD7E5CB-4D6F-4388-97CC-D51589F28063</gtr:id><gtr:outcomeId>220C830E8430</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Using Adenoviruses to Target Inflammatory Cytokines - Gene Delivery of Biological Therapies in Ovarian Cancer</gtr:description><gtr:fundingOrg>Ovarian Cancer Action</gtr:fundingOrg><gtr:id>0382AEC1-A95C-4D30-B177-047605002157</gtr:id><gtr:outcomeId>EBD88D6C6EA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>118848</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding (Inflammatory Cytokines and Malignant Transformation of the Ovarian Surface Epithelium)</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>FE7A0EF9-658B-4A05-83ED-59351A1D1849</gtr:id><gtr:outcomeId>E3370D55AAF0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>196581</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centocor Inc funding (Pre-Clinical Studies on an Anti-CCL2 Antibody in Ovarian Cancer)</gtr:description><gtr:fundingOrg>Janssen Biotech, Inc.</gtr:fundingOrg><gtr:id>57EE4E03-24EE-48D9-88B4-5B92F11701F6</gtr:id><gtr:outcomeId>326D88C586E0</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Targeting the peritoneal tumour microenvironment of high grade serous ovarian cancer</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>DCC4DC07-04F9-46E7-B226-761C1FA3A11B</gtr:id><gtr:outcomeId>5462071e6ca5a3.72527743</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>159000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding (Targeting the Chemokine Receptor CCR4 in Epithelial Cancer)</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>03EEAA8B-6975-4205-82AD-E21D7D6E9D30</gtr:id><gtr:outcomeId>6147C50C5AC0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>204706</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding (Generation of Anitbodies Agaisnt the Chemokine CXCL12 for Cancer Therapy)</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>DB62743F-94A6-4182-BDFB-9ED16523F5AE</gtr:id><gtr:outcomeId>7DC30119F520</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>59577</gtr:amountPounds><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Institute of Biotechnology</gtr:department><gtr:description>PhD Studentship</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Vietnam Academy of Science and Technology</gtr:fundingOrg><gtr:id>593068E6-B8F5-4E08-8DE4-2AEE7B60326B</gtr:id><gtr:outcomeId>54620a297131b7.49510836</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>201042</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR funding (Targeting CXCR4 and Its Ligand in Ovarian Cancer)</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>C3CEA3BF-A13C-4FEA-B5D6-86713B4A67E9</gtr:id><gtr:outcomeId>34B8FA602980</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>487000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centocor Inc funding (Support for Pre-Clinical and Clinical Studies with Infliximab)</gtr:description><gtr:fundingOrg>Janssen Biotech, Inc.</gtr:fundingOrg><gtr:id>668B9464-DB41-4CA0-A332-86F7544178DD</gtr:id><gtr:outcomeId>B3ECBA8A2820</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The potential of the chemokine receptor CCR4 as a cancer marker and therapeutic target</gtr:description><gtr:grantRef>G0501974</gtr:grantRef><gtr:id>AAF5E60A-72CD-4139-8F0D-35E5888EA1B5</gtr:id><gtr:impact>Funding for development of a potential clinical trial</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>546216990769d5.49620218</gtr:outcomeId><gtr:patentId>Application No: PCT/GB2008/003160 (RAW/P118375US)</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>CCR4 Cancer Marker and Therapeutic Target Patent</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chair of Council of Understanding Animal Research, UAR</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>465215DB-9FB5-4F24-8963-0F360F9E379A</gtr:id><gtr:impact>The concordat of Openness in animal research</gtr:impact><gtr:outcomeId>546215f1c28bd3.49548611</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://www.understandinganimalresearch.org.uk/policy/concordat-on-openness-on-animal-research/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The trial was completed in 2009 G0501974 EUDRACT 2006-005704-13 and was published in 2011 (recorded in publication list above). Both myself and the clinical P.I. Iain McNeish are seeking further funding for further clinical trials and carrying out pre-clinical development to support such trials. The antibody used in the above trial is nearing reulatory approval from the FDA for use in Castlemann's disease.</gtr:description><gtr:id>9FFF7586-EC9F-44A8-BFE4-FF9CC52BF4C8</gtr:id><gtr:impact>Both myself and the clinical P.I. Iain McNeish are seeking further funding for further clinical trials and carrying out pre-clinical development to support such trials. The antibody used in the above trial is nearing reulatory approval from the FDA for use in Castlemann's disease. The clinical and pre-clinical studies funded by the MRC grant were instrumental in my obtaining a new CRUK programme grant.

grant of &amp;pound;1.5mill</gtr:impact><gtr:outcomeId>P9pKqYgAvYx</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>A Phase II study of an anti-IL-6 antibody in ovarian cancer</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>G0501974</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4D258665-2E5C-4CE2-9E59-1CD787145875</gtr:id><gtr:title>Cancer. Sex, cytokines, and cancer.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9840fd94b2f1df7980e154fd24bf3379"><gtr:id>9840fd94b2f1df7980e154fd24bf3379</gtr:id><gtr:otherNames>Lawrence T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>6BAA80ACB23</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCDC5210-D54D-4E4E-82E9-E6D35CEFF593</gtr:id><gtr:title>IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c11f0fc7f828a365a5b00dfb947462a"><gtr:id>1c11f0fc7f828a365a5b00dfb947462a</gtr:id><gtr:otherNames>Karagiannis SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>E168435827A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2339D42E-877F-491E-A434-679C4B03C267</gtr:id><gtr:title>Tumour necrosis factor-alpha as a tumour promoter.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b4215045f2e85365cf421b6981e7a73"><gtr:id>4b4215045f2e85365cf421b6981e7a73</gtr:id><gtr:otherNames>Szlosarek P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>9CE42DFAF75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D71D9C5-7CE3-4F96-805A-7AC1CB9BA819</gtr:id><gtr:title>Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57aaaf68aab5e88079f0a409904ce38a"><gtr:id>57aaaf68aab5e88079f0a409904ce38a</gtr:id><gtr:otherNames>Szlosarek PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>3246B6122AD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80C88283-29EC-4C65-8FFE-B6D2F0DE4803</gtr:id><gtr:title>Interleukin-6 as a therapeutic target in human ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c9c1dac2bfb471e420a214860155f02"><gtr:id>7c9c1dac2bfb471e420a214860155f02</gtr:id><gtr:otherNames>Coward J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>CQRPNH7xvTf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0254158E-7173-4F4F-8B98-16B61256561B</gtr:id><gtr:title>Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbc1cac1a07dae4a1e68fa8b6b4a34ce"><gtr:id>fbc1cac1a07dae4a1e68fa8b6b4a34ce</gtr:id><gtr:otherNames>Milagre CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5675dfa27adab</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3590793B-93F9-4086-A5FF-7135AA88AB4B</gtr:id><gtr:title>CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32c9dae04e04bbb50c4b8ec949072b88"><gtr:id>32c9dae04e04bbb50c4b8ec949072b88</gtr:id><gtr:otherNames>Walton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>58c6fe83790bd9.31947898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>291DD987-5A58-433E-9CA0-1B9003DCEB18</gtr:id><gtr:title>10th Biennial Helene Harris Memorial Trust meeting.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfd902aa971f0f3c6b72660d00692ef5"><gtr:id>bfd902aa971f0f3c6b72660d00692ef5</gtr:id><gtr:otherNames>Balkwill FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>8BF23A98CA6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A5CE4A0-112A-45B5-AA4B-3E9F37E3B160</gtr:id><gtr:title>A novel function of colony-stimulating factor 1 receptor in hTERT immortalization of human epithelial cells.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7480c8c1ba19183a54c1ea59c8db926d"><gtr:id>7480c8c1ba19183a54c1ea59c8db926d</gtr:id><gtr:otherNames>Li NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5D38D08EFF2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>436E1B7E-C3D5-46B8-A4A0-7A7B9C32AC43</gtr:id><gtr:title>No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c5ab9200953369c5478cbe97e007ebc"><gtr:id>5c5ab9200953369c5478cbe97e007ebc</gtr:id><gtr:otherNames>Sucheston-Campbell LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>58c6fe824ed393.44935448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F104B68B-F72C-46BD-BE7F-FD6CA3DCF399</gtr:id><gtr:title>Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression.</gtr:title><gtr:parentPublicationTitle>Cell proliferation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7480c8c1ba19183a54c1ea59c8db926d"><gtr:id>7480c8c1ba19183a54c1ea59c8db926d</gtr:id><gtr:otherNames>Li NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-7722</gtr:issn><gtr:outcomeId>AB37CE4E9E1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C153514F-27CB-4243-8133-567635F76A73</gtr:id><gtr:title>Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells.</gtr:title><gtr:parentPublicationTitle>Neoplasia (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6705a114d360fed503771920693d7a2e"><gtr:id>6705a114d360fed503771920693d7a2e</gtr:id><gtr:otherNames>Kwong J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1476-5586</gtr:issn><gtr:outcomeId>22457ABCE78</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32873715-4855-467B-B263-08FD3F9D016E</gtr:id><gtr:title>Interleukin-6 Stimulates Defective Angiogenesis.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a0fcd8b34126782499d3a07f134f63e"><gtr:id>7a0fcd8b34126782499d3a07f134f63e</gtr:id><gtr:otherNames>Gopinathan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>56caf40009e183.90695534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A36FBEB-DE8C-462F-B506-5B3FE8F85490</gtr:id><gtr:title>The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1aeabcd4ae4e875e598fdac6506e39c8"><gtr:id>1aeabcd4ae4e875e598fdac6506e39c8</gtr:id><gtr:otherNames>Clarke CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>58c6fe848dcc10.85529032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E1311E0-4147-4495-887D-979EDB70C04D</gtr:id><gtr:title>A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe09e7ce4e63bf13625cea1564da9e2"><gtr:id>7fe09e7ce4e63bf13625cea1564da9e2</gtr:id><gtr:otherNames>Kulbe H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>54537514ef1963.98947720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9246B2D8-DD86-4305-A784-CCCF113BB391</gtr:id><gtr:title>Inflammation and cancer: a double-edged sword.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>09522C81A0F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3302A22D-014D-42E1-A639-2C5F11D7D0EA</gtr:id><gtr:title>Murine CD27(-) V?6(+) ?d T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad9263e2b009da714fa66770ffa55262"><gtr:id>ad9263e2b009da714fa66770ffa55262</gtr:id><gtr:otherNames>Rei M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>54525f04b3ad24.66224921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>910153BE-5AD6-4356-B561-EC40D9E60276</gtr:id><gtr:title>Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2e3f73fef7ddf148a790d78762c7669"><gtr:id>f2e3f73fef7ddf148a790d78762c7669</gtr:id><gtr:otherNames>Leinster DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>5453747ecd7d53.81889196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FA262FB-EAD0-40F9-B55B-DC796E4074DF</gtr:id><gtr:title>Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.</gtr:title><gtr:parentPublicationTitle>Cancer discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a98687e7c5035ccb72273381ed7ac1c7"><gtr:id>a98687e7c5035ccb72273381ed7ac1c7</gtr:id><gtr:otherNames>Kar SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2159-8274</gtr:issn><gtr:outcomeId>58c6fe83b7a237.68636540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08322CB3-DB1B-4AB1-8809-2932D2F2815B</gtr:id><gtr:title>Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57aaaf68aab5e88079f0a409904ce38a"><gtr:id>57aaaf68aab5e88079f0a409904ce38a</gtr:id><gtr:otherNames>Szlosarek PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>92C88D35570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6E90805-5BEB-4085-BB60-857F630C4286</gtr:id><gtr:title>Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a98687e7c5035ccb72273381ed7ac1c7"><gtr:id>a98687e7c5035ccb72273381ed7ac1c7</gtr:id><gtr:otherNames>Kar SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58c6fe81191097.71174392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD6B546C-3F5A-4A10-9986-CCCCDEE9E500</gtr:id><gtr:title>Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c11f0fc7f828a365a5b00dfb947462a"><gtr:id>1c11f0fc7f828a365a5b00dfb947462a</gtr:id><gtr:otherNames>Karagiannis SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn><gtr:outcomeId>B0805EA60CF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F74F5B9C-DBE2-460F-907E-73C527E26845</gtr:id><gtr:title>Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype?</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47021f183ffb28ee647717b052819372"><gtr:id>47021f183ffb28ee647717b052819372</gtr:id><gtr:otherNames>McNeish IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>58c6fe8405da10.77492036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3C40522-033A-4B08-A6C1-5950710C54E0</gtr:id><gtr:title>Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21898f6af6ebf0a3c60025bcb167c403"><gtr:id>21898f6af6ebf0a3c60025bcb167c403</gtr:id><gtr:otherNames>McGee J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>58c6fe80b0a132.23925866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A045996B-45AE-49F1-8437-B3C188690D94</gtr:id><gtr:title>Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a96cb7e4c378a7e097d2e00aaae7ebde"><gtr:id>a96cb7e4c378a7e097d2e00aaae7ebde</gtr:id><gtr:otherNames>Swisher EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>58c6fe82117085.86025112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>056F931E-2B93-4008-9B49-F22097B84E0A</gtr:id><gtr:title>Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df6453c3688944f06891ef90051fb5b1"><gtr:id>df6453c3688944f06891ef90051fb5b1</gtr:id><gtr:otherNames>Bowtell DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>56caf5427e7c24.87867661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6936D393-C3E2-4326-863E-018B22C1146F</gtr:id><gtr:title>Inhibition of the inflammatory cytokine TNF-a increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a468e59184e25256296033a3033450c2"><gtr:id>a468e59184e25256296033a3033450c2</gtr:id><gtr:otherNames>Salako MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>nabBw3K7djh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFA2976E-E87B-4277-8B2A-3F0B89982FA0</gtr:id><gtr:title>The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe09e7ce4e63bf13625cea1564da9e2"><gtr:id>7fe09e7ce4e63bf13625cea1564da9e2</gtr:id><gtr:otherNames>Kulbe H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>1E64663077C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF60F721-24CA-4727-9878-D8AE7FC92457</gtr:id><gtr:title>Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2dde8b45ba592fe86bc09dc89293d39"><gtr:id>f2dde8b45ba592fe86bc09dc89293d39</gtr:id><gtr:otherNames>Strauss SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>8382F3A2810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91B774EE-4EC5-4FC7-92A5-CB9F6F3DF718</gtr:id><gtr:title>Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0aeaf992507d9d4c8d649b5e2c240ac8"><gtr:id>0aeaf992507d9d4c8d649b5e2c240ac8</gtr:id><gtr:otherNames>Lau TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>545261eac6c8a2.30663956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>967AEBD5-005E-4830-8E63-311FD35ACF30</gtr:id><gtr:title>Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>37D45B758C0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A15122A6-2F43-4AB6-A0CC-2ED6E9800C45</gtr:id><gtr:title>Paraneoplastic thrombocytosis in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d05bf6b6f0ea3603306e5ba353c5cf2"><gtr:id>3d05bf6b6f0ea3603306e5ba353c5cf2</gtr:id><gtr:otherNames>Stone RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_14781_21_22335738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64F107E5-11AE-43D4-8463-F845B6AC0405</gtr:id><gtr:title>Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba2eda461d2abc1cb73279a72f833206"><gtr:id>ba2eda461d2abc1cb73279a72f833206</gtr:id><gtr:otherNames>Toulza F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>MzCy9vH23Lt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAF7BAB2-2179-4F41-A08B-82ED52CFCFC0</gtr:id><gtr:title>PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9e53e397154259a9664500d40dd4570"><gtr:id>f9e53e397154259a9664500d40dd4570</gtr:id><gtr:otherNames>Southey MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>58c6fe82dbc0f1.59548170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3D6AC9D-F72B-4923-9005-ADEB64E9342A</gtr:id><gtr:title>Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6cd8cbbac729ab25bf9d16871a86bc8"><gtr:id>f6cd8cbbac729ab25bf9d16871a86bc8</gtr:id><gtr:otherNames>Saadi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>Kve1YSsgHVB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45EB2069-6C28-490D-A4B5-D8FB153F33B4</gtr:id><gtr:title>Inflammation and cancer: advances and new agents.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ddd6af6f82dfd5ca496430fd1a81007"><gtr:id>7ddd6af6f82dfd5ca496430fd1a81007</gtr:id><gtr:otherNames>Crusz SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>56caf54305ae50.29267532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2284241D-8D98-4D87-8BF5-9D79E9E3E5AF</gtr:id><gtr:title>Cancer-related inflammation.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea497b24b289c2966f88bc99cbe2f73"><gtr:id>2ea497b24b289c2966f88bc99cbe2f73</gtr:id><gtr:otherNames>Mantovani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>CC241AAC442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CB209F2-021D-4A4B-B2ED-27BB8F6501FD</gtr:id><gtr:title>Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007.</gtr:title><gtr:parentPublicationTitle>Gynecologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5184b8d258ef842a7703855aa790bde2"><gtr:id>5184b8d258ef842a7703855aa790bde2</gtr:id><gtr:otherNames>Ashworth A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0090-8258</gtr:issn><gtr:outcomeId>8C3BDE78D59</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66480208-CCC9-4A05-9479-D6CBAD0DB3E0</gtr:id><gtr:title>RalB signaling: a bridge between inflammation and cancer.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea497b24b289c2966f88bc99cbe2f73"><gtr:id>2ea497b24b289c2966f88bc99cbe2f73</gtr:id><gtr:otherNames>Mantovani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>90236EB81E0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAD08625-A00A-4EFA-B5CD-A3D543483C58</gtr:id><gtr:title>Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/552cb238fc8faa71eecf5b6317172feb"><gtr:id>552cb238fc8faa71eecf5b6317172feb</gtr:id><gtr:otherNames>Lawrenson K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c6fe82909052.14952573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3D7C76A-D4C3-4434-B831-379F87E8A568</gtr:id><gtr:title>Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e75654cef6e7d03e0b9c6036bd663b7f"><gtr:id>e75654cef6e7d03e0b9c6036bd663b7f</gtr:id><gtr:otherNames>Harrison ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>73786043D39</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7C52E38-3BF6-4B4B-A417-BCE3280A6E54</gtr:id><gtr:title>Tumour necrosis factor and cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eaae728664cd48c86a5fe06b15d3c5a0"><gtr:id>eaae728664cd48c86a5fe06b15d3c5a0</gtr:id><gtr:otherNames>Balkwill F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>0BB8E1738C0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDF6A9D3-AD41-411A-9EF5-0E77E3C5184A</gtr:id><gtr:title>Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe09e7ce4e63bf13625cea1564da9e2"><gtr:id>7fe09e7ce4e63bf13625cea1564da9e2</gtr:id><gtr:otherNames>Kulbe H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>56caf4bd2ef6d4.87267518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF4D2288-7C9E-455B-A4AF-5944BB4E50BE</gtr:id><gtr:title>Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05edb93ba89c577e9e72d1cc86cd3f49"><gtr:id>05edb93ba89c577e9e72d1cc86cd3f49</gtr:id><gtr:otherNames>Permuth JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58c6fe81c424b0.24193268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B99C85E-2322-4748-9D6F-16BCA4A9C694</gtr:id><gtr:title>p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ae38f4230ee7fff590c132d18ee916f"><gtr:id>7ae38f4230ee7fff590c132d18ee916f</gtr:id><gtr:otherNames>Flak MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>JyQHTKjsrDG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04E2CF57-E1E8-4FAB-BE86-6008CEC12BBF</gtr:id><gtr:title>&amp;quot;Re-educating&amp;quot; tumor-associated macrophages by targeting NF-kappaB.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>F5DAC6A4F06</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00D85DE5-972F-437A-B84C-C5F4DEF7F7BB</gtr:id><gtr:title>Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/198617ec409b86c559b786d400fc473e"><gtr:id>198617ec409b86c559b786d400fc473e</gtr:id><gtr:otherNames>Hernandez-Fernaud JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c6fe80649710.20351996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02E75D35-8EDE-4BC2-80B3-F49EB8CD7AE3</gtr:id><gtr:title>Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>EF05C161203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D158F7B-367F-43BB-92A0-55C970422FBD</gtr:id><gtr:title>In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57aaaf68aab5e88079f0a409904ce38a"><gtr:id>57aaaf68aab5e88079f0a409904ce38a</gtr:id><gtr:otherNames>Szlosarek PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>42CAE46BE40</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>866C5EC8-053A-41BB-9197-4D8730BD0A01</gtr:id><gtr:title>Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f370d46888ebecf0e88a36ed51e7c26"><gtr:id>3f370d46888ebecf0e88a36ed51e7c26</gtr:id><gtr:otherNames>Hampras SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58c6fe83366031.26280382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9935E01E-6885-4AA8-9B79-0658E2ED49D4</gtr:id><gtr:title>IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f533702151ac4c49d0f9c4c125d715e1"><gtr:id>f533702151ac4c49d0f9c4c125d715e1</gtr:id><gtr:otherNames>Anglesio MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>Sfxa4vdiSzh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E0082CA-054E-4A0F-8438-69B0D6FA0AC3</gtr:id><gtr:title>Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3338305b53006620bdd5390546872d7e"><gtr:id>3338305b53006620bdd5390546872d7e</gtr:id><gtr:otherNames>Babic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn><gtr:outcomeId>58c6fe81598df4.14086145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CA947DC-C689-4F45-A160-5F7099C6596B</gtr:id><gtr:title>The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f880434fe71f517be824fe857dc1c022"><gtr:id>f880434fe71f517be824fe857dc1c022</gtr:id><gtr:otherNames>Charles KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>9B302BC43A0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E526CA5F-245E-4A49-839B-F63B7EE3B0B0</gtr:id><gtr:title>An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6705a114d360fed503771920693d7a2e"><gtr:id>6705a114d360fed503771920693d7a2e</gtr:id><gtr:otherNames>Kwong J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>7D6197D50E0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3089103-4CBE-46DE-ABA4-34A5C243A839</gtr:id><gtr:title>A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cd00cb687a94eee2b2d039ec229f78a"><gtr:id>9cd00cb687a94eee2b2d039ec229f78a</gtr:id><gtr:otherNames>Brown ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>F75ECDB5A10</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>890CA474-9835-4C61-A065-BFDE9D902734</gtr:id><gtr:title>TNF-alpha in promotion and progression of cancer.</gtr:title><gtr:parentPublicationTitle>Cancer metastasis reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eaae728664cd48c86a5fe06b15d3c5a0"><gtr:id>eaae728664cd48c86a5fe06b15d3c5a0</gtr:id><gtr:otherNames>Balkwill F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0167-7659</gtr:issn><gtr:outcomeId>95B9FE24154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F53930E-D4B5-46D0-89F6-DE741CED1DCA</gtr:id><gtr:title>Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cb4afe72d10ddbb75d0cf57bf052c9b"><gtr:id>0cb4afe72d10ddbb75d0cf57bf052c9b</gtr:id><gtr:otherNames>B?hm S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>58c6fe84491da6.93583980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D792603-A700-4DAB-B7EB-5027368364F1</gtr:id><gtr:title>Rethinking ovarian cancer: recommendations for improving outcomes.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/986ed0b4f03a4d505348b2b881d0bb81"><gtr:id>986ed0b4f03a4d505348b2b881d0bb81</gtr:id><gtr:otherNames>Vaughan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>Bg9HqeRdsMG</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501974</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>